v3.25.2
Segment Reporting - Schedule of Our Chief Officer Decision Maker Evaluates Segment Performance (Details) - USD ($)
 3 Months Ended 12 Months Ended
Apr. 30, 2025
Apr. 30, 2024
Jan. 31, 2025
Jan. 31, 2024
Net sales        
Net sales $ 667,432 $ 408,532 $ 2,139,537 $ 2,085,314
Gross profit        
Gross profit 251,981 164,786 743,317 862,105
Operating expenses        
Operating expenses 1,665,478 2,054,263 11,028,160 5,734,031
Depreciation and Amortization        
Depreciation and Amortization 57,480 69,101 285,054 287,722
Pocono Pharmaceuticals [Member]        
Net sales        
Net sales 667,432 408,532    
Gross profit        
Gross profit 251,981 164,786 743,317 744,391
Depreciation and Amortization        
Depreciation and Amortization 48,213 56,823 235,941 222,159
4P Therapeutics [Member]        
Net sales        
Net sales    
Gross profit        
Gross profit 117,714
Depreciation and Amortization        
Depreciation and Amortization 9,267 9,267 37,070 51,577
Selling, general and administrative-Pocono Pharmaceuticals [Member]        
Operating expenses        
Operating expenses 151,528 154,394 661,805 606,275
Selling, general and administrative-4P Therapeutics [Member]        
Operating expenses        
Operating expenses 19,999 24,354 136,294 236,953
Selling, general and administrative-Corporate [Member]        
Operating expenses        
Operating expenses 810,525 900,980 3,515,711 2,930,378
Research and development-4P Therapeutics [Member]        
Operating expenses        
Operating expenses 683,426 974,535 3,119,134 1,960,425
Corporate [Member]        
Depreciation and Amortization        
Depreciation and Amortization $ 3,011 $ 12,043 $ 13,986